Trials / Conditions / Refractory Lymphoplasmacytic Lymphoma

Refractory Lymphoplasmacytic Lymphoma

10 registered clinical trials studyying Refractory Lymphoplasmacytic Lymphoma — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810	Mayo Clinic	Phase 1
Withdrawn	Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lym NCT04635683	Yazeed Sawalha	Phase 1
Completed	CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymph NCT04578600	Joseph Tuscano	Phase 1
Active Not Recruiting	Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma NCT03479268	City of Hope Medical Center	Phase 1
Active Not Recruiting	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Exp NCT03277729	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma NCT03015896	David Bond, MD	Phase 1 / Phase 2
Completed	Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT02950220	Kami Maddocks	Phase 1
Completed	Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic L NCT02332980	Mayo Clinic	Phase 2
Active Not Recruiting	Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma NCT01955499	National Cancer Institute (NCI)	Phase 1
Completed	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099	Fred Hutchinson Cancer Center	Phase 2